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efﬁcacy than latanoprost in controlling the IOP for patients with
ocular hypertension or glaucoma.
PEY6
A PUBLIC HEALTH IMPACT MODEL OF ANECORTAVE
ACETATE IN WET AGE-RELATED MACULAR DEGENERATION
Deschaseaux-Voinet C1, Lafuma A1, Berdeaux G2
1Cemka Eval, Bourg-la-Reine, Hauts de Seine, France; 2Alcon France
SA, Rueil-Malmaison, Hauts de Seine, France
OBJECTIVE: This study aimed at estimating the potential public
health impact of Retaane 15mg (anecortave acetate suspen-
sion)in age-related macular degeneration. METHODS: Based on
clinical trial results and literature, a Markov model was built to
compare anecortave acetate to best supportive care (BSC) during
the lifetime of ARMD patients. Patients entering the model were
75 years of age with a new diagnosis of wet ARMD in one eye.
This model took into account the efﬁcacy of anecortave acetate
to slow deterioration and delay visual disability, the probability
for a patient to develop the disease in the fellow eye, and mor-
tality. Results of the model were expressed in terms of duration
of low vision (with blindness in one eye) and blindness in both
eyes. Health consequences of blindness and low vision were esti-
mated for depression and hip fractures as well as for institu-
tionalization. Duration of the model was 25 years and the cycle
length was 1 month. The fellow eye could be affected in 30% of
the patients at ﬁve years. Premature mortality associated with
blindness and low vision was estimated. RESULTS: Anecortave
acetate decreased the number of prevalent blind cases by 20%
and the average time with blindness by 30%. Depression preva-
lent cases were decreased by 21% and those with hip fracture
by 10%. The number of patients who were institutionalized was
decreased by 27%. Decrease in life expectancy due to premature
mortality associated with blindness and low vision could be esti-
mated at 17% in the BSC group and 15.5% in the anecortave
acetate group. Life expectancy was increased by 3 months.
CONCLUSION: Anecortave acetate presents important and
favorable potential public health outcomes in patients with wet
ARMD. According to the model it could reduce the rates of
depression, hip fractures and institutionalization, and increase
life expectancy compared with BSC.
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OBJECTIVE: To estimate the number of treatable eyes with wet
sub-foveal ARMD in France. METHODS: Surveys documenting
wet ARMD incidence rate were searched in the literature. Direct
standardization according to age and gender was performed
using INSEE demographic data. Projection at year 2025 was per-
formed using OECD data. A 75 years old cohort was simulated
using a 7-states Markov model. Mean treatment duration of
New Chemical Entity is not known today and therefore was
ﬁxed arbitrarily at 2 years. The probability to develop ARMD
in the fellow eye was ﬁxed at 30% at 5 years. Monthly death
incidence rate was modeled from INSEE mortality tables. The
time horizon of the model was 25 years and the cycle length 
one month. Sensitivity analyses were performed. RESULTS: 3
surveys were identiﬁed. The Rotterdam Study, the only one per-
formed in the EU, was chosen as the best proxy for France. In
2005, 30,192 citizens will develop ARMD in the ﬁrst eye; of
those 17,585 will be wet and 13,805 will be wet sub-foveal
(Olsen, 2004). Taking into account the fellow eye, mortality and
the base case scenario treatment duration, the number of wet
sub-foveal treatable eyes would be 37,019. Treatment duration
is the most sensitive parameter of the model. Number of eyes
would be 18,899, 53,204, 67,535, and 80,162 for a treatment
duration of 1, 3, 4 and 5 years, respectively. The number of treat-
able eyes will increase by 7.1% if probability to develop the
disease in the second eye is 40%, and decrease by -9.0% if it is
20%. A 2% yearly increase is expected till 2025 due to popula-
tion aging and the 1950s’ baby-boom. CONCLUSION: Accord-
ing to our model, the number of sub-foveal wet ARMD treatable
eyes would be 37,019, in France. Average treatment duration
was the most sensitive parameter.
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OBJECTIVE: LASEK is one of the current surgical technique to
correct refractive errors of the eye, such as myopia, hyperopia,
and astigmatism. In this method, the corneal epithelial ﬂap is
lifted then replaced after laser ablation of the subepithelial
cornea. The hinged ﬂap is created by epithelial marking and
exposure of the marking ethyl alcohol (20%) for 5 seconds.
METHODS: LASIK (Laser in Situ Keratomileusis) is a surgical
procedure to correct myopia by corneal stroma subtraction. It
involves the use of a microkeratome to make a lamellar dissec-
tion of the cornea creating a ﬂap with intact corneal epithelium.
After the ﬂap is lifted, the underlying midstroma is reshaped with
an excimer laser and the ﬂap is returned to its original position.
We have detected eighteen cases where the treatment of patients
that had been subjected to LASEK with polyvinyl alcohol artiﬁ-
cial tear drops provoked eye adverse effects. Toxicogenic kerati-
tis, partial epithelium detachment, and allergic and toxicogenic
conjunctivitis were observed. These adverse effects disappeared
upon discontinuing tear drops administration and reappeared
after their reintroduction. We used the Naranjo et al. algorithm
to conﬁrm the cause-effect relationship. RESULTS: All cases
were conﬁrmed as deﬁnitive. CONCLUSION: We have not
observed any case of eye adverse effect in patients subjected to
LASIK caused by polyvinyl alcohol tear drops.
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OBJECTIVE: To develop a health-economic assessment for
Macugen, a new treatment for age-related macular degeneration
(AMD). A comprehensive model compares Macugen (pegap-
tanib sodium), indicated for all patients with neovascular AMD,
relative to the existing photodynamic therapy with Visudyne
(verteporﬁn). METHODS: A Markov framework was used to
model the lifetime movement of an AMD cohort through ﬁve
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health states based on visual acuity (VA): >20/40, 20/40 to
>20/80, 20/80 to >20/200, 20/200 to >20/400, and >20/400. The
model incorporates patients across all lesion subtypes: predom-
inately classic, minimally classic, and occult. All drug and pro-
cedure costs were derived from US published sources, including
Medicare Part B Drugs Average Sales Price and RBRVS. Expert
interviews were conducted to determine adverse events treatment
patterns and vision rehabilitation resource use. Relative risks and
costs associated with effects associated with declining VA
(depression, bone fractures, skilled nursing facilities, and nursing
homes) were extracted from a Medicare analysis. Transition
probabilities were derived from published trial data for both
products for each of the 3-month cycles. Utilities were derived
from similar published sources as previous AMD models. Results
are expressed as vision years, quality-adjusted life years
(QALYs), medical costs and other costs, as well as the average
cost per vision year and QALY gained. RESULTS: For a lifetime
analysis the average cost per vision year was $20,459 for
Macugen and $26,079 for Visudyne and the average cost per
QALY was $19,609 for Macugen and $20,136 for PDT. A
patient treated with Macugen had on average 3.68 vision years
over a lifetime compared to 2.65 for a patient treated with Visu-
dyne. CONCLUSIONS: Macugen treatment produces more
years of sight than Visudyne for AMD treated patients. Macugen
is more cost-effective versus active treatment with Visudyne. A
limitation of the model is the absence of direct clinical compar-
ison between the products.
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OBJECTIVES: Many patients suffering from glaucoma ﬁnd it
necessary to use a second adjunctive topical agent to adequately
reduce the intraocular pressure (IOP). New more convenient
ﬁxed combination products containing two active anti-glaucoma
medications have been developed. The objective of this analysis
is to compare the cost of brimonidine/timolol ﬁxed combination
(Combigan®) with concomitant administration of brimonidine
(Alphagan®) and timolol, dorzolamide/timolol ﬁxed combina-
tion (Cosopt®), and concomitant administration of dorzolamide
(Trusopt®) and timolol. METHODS: RCTs have documented
equivalent safety and efﬁcacy in terms of IOP control of combi-
nation products in comparison with their individual components
(Sall et al., 2003; Solish et al., 2004). A cost-minimization analy-
sis including drug costs and visits at the ophthalmologist was
carried out for UK and other European counties with both a
health care and drug alone perspective. An RCT (Simmons et al.,
2001) has shown that Alphagan+timolol was more effective than
Trusopt+timolol in terms of patients achieving target IOP, there-
fore a cost-effectiveness analysis was constructed for this com-
parison. RESULTS: The 3-months health care costs analysis
(drug alone) in the UK using Combigan was £264.00 (£30.00)
compared with £268.11 (£34.11) for Alphagan+timolol and
£264.15 (£30.15) for Cosopt. With a 12-months perspective,
including additional drug and visits, the health care costs (drug
alone) rose to £510.00 (£120.00) for Combigan compared 
with £526.44 (£136.44) for Alphagan+timolol and £510.60
(£120.60) for Cosopt. The cost-effectiveness analysis docu-
mented that Alphagan was more cost-effective than Trusopt
adjunctively. CONCLUSION: Combigan provided better cost
value than Alphagan+timolol adjunctively. The use of Combigan
instead of Alphagan+timolol would result in annual societal
savings of around £728,000 in the UK. Combigan resulted in
slightly lower health care costs when modeling equal effective-
ness compared with Cosopt.
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OBJECTIVE: To compare the cost-effectiveness of early treat-
ment in disease progression of age-related macular degeneration
(AMD) to later treatment. A comprehensive model compares
starting treatment with Macugen (pegaptanib sodium), a new
treatment for AMD indicated for all patients with neovascular
AMD and standard care in patients with early disease progres-
sion (i.e., better visual acuity [VA]) versus late disease progres-
sion (i.e., worse VA). METHODS: A Markov framework was
used to model lifetime movement of an AMD cohort through
health states based on VA: >20/40, 20/40 to >20/80, 20/80 to
>20/200, 20/200 to >20/400, and >20/400. Drug and procedure
costs were derived from US published sources. Expert interviews
were conducted to determine adverse events treatment patterns
and vision rehabilitation resource use. Relative risks and costs
associated with effects associated with declining VA were
extracted from a Medicare analysis. Transition probabilities
were derived from published trial data for both products for each
of the 3-month cycles. Utilities were derived from similar pub-
lished sources as previous AMD models. Results are expressed
as vision years, quality-adjusted life years (QALYs), medical
costs, and other costs, as well as the incremental cost per vision
year and QALY gained. Three runs of the model were conducted
with cohorts of patients starting in one of the following health
states: 20/40 to >20/80; 20/80 to >20/200; and 20/200 to
>20/400. RESULTS: For lifetime analysis incremental cost-
effectiveness ratios (ICERs) per vision year gained were $19,744,
$23,377, and $58,512 and ICERs per QALY gained were
$46,911, $67,058, and $135,400 versus standard care for
patients started in the 20/40 to >20/80, 20/80 to >20/200, and
20/200 to >20/400 states, respectively. CONCLUSIONS: Treat-
ing patients early when presenting with AMD results in lower
ICERs than waiting to treat patients until their VA worsens. To
achieve maximum cost beneﬁts treatment should begin as soon
as possible.
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OBJECTIVE: To estimate the efﬁciency of latanoprost against
the ﬁxed-combination of dorzolamide/timolol in treating
patients with glaucoma in Spain. METHODS: A cost-minimiza-
tion analysis was carried out by building a decision analytical
model, because the effectiveness of both therapeutic options 
in lowering intraocular pressure (IOP) was similar in a per-
formed systematic review of the literature. However, dorzo-
lamide/timolol was associated with a higher incidence of adverse
